142 229

Cited 0 times in

Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate

DC FieldValueLanguage
dc.contributor.author박용범-
dc.contributor.author박희진-
dc.contributor.author이상원-
dc.contributor.author이수곤-
dc.contributor.author한광협-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.date.accessioned2014-12-19T16:29:41Z-
dc.date.available2014-12-19T16:29:41Z-
dc.date.issued2012-
dc.identifier.issn1478-6354-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/89635-
dc.description.abstractABSTRACT: INTRODUCTION: We identified silent liver fibrosis in patients with rheumatoid arthritis (RA) using transient elastography, and investigated medication that correlated with abnormal liver stiffness measurement (LSM) values. METHODS: We consecutively enrolled 105 patients with RA taking methotrexate over 24 weeks with normal liver functions and no history of underlying chronic liver disease. Blood tests were performed, and body mass index and metabolic syndrome were assessed. We checked LSM values, and adopted 5.3 kPa as the cutoff for abnormal LSM values. The cumulative doses of medications including methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, prednisolone, meloxicam, and celecoxib were calculated. RESULTS: The median age of patients (20 men and 85 women) was 52.4 years. The median LSM value was 4.7 kPa and 24 (22.9%) patients had abnormal LSM values. Gamma-glutamyltranspeptidase levels and the cumulative doses of leflunomide and prednisolone significantly correlated with LSM values (P<0.05). The cumulative dose of leflunomide, but not methotrexate, was significantly higher in patients with abnormal LSM values than that in patients with normal LSM values (P = 0.008). When RA patients receiving leflunomide plus methotrexate were classified into two groups according to the optimal cutoff cumulative dose of leflunomide (19,170 mg), abnormal LSM values were more frequently identified in patients with high cumulative dose of leflunomide (odds ratio, 12.750; P<0.001). CONCLUSIONS: The cumulative dose of leflunomide was the only independent predictor of abnormal LSM values in patients with RA who had received methotrexate for more than six months.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfARTHRITIS RESEARCH & THERAPY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAntirheumatic Agents/adverse effects*-
dc.subject.MESHAntirheumatic Agents/therapeutic use*-
dc.subject.MESHArthritis, Rheumatoid/drug therapy*-
dc.subject.MESHCross-Sectional Studies-
dc.subject.MESHDose-Response Relationship, Drug-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHElasticity Imaging Techniques-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHIsoxazoles/adverse effects*-
dc.subject.MESHIsoxazoles/therapeutic use*-
dc.subject.MESHLiver/diagnostic imaging-
dc.subject.MESHLiver/physiopathology-
dc.subject.MESHLiver Cirrhosis/diagnosis-
dc.subject.MESHLiver Cirrhosis/epidemiology*-
dc.subject.MESHLiver Cirrhosis/physiopathology-
dc.subject.MESHMale-
dc.subject.MESHMethotrexate/therapeutic use*-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHRisk Factors-
dc.titleLeflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSang-Won Lee-
dc.contributor.googleauthorHee-Jin Park-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorSoo-Kon Leee-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorYong-Beom Park-
dc.identifier.doi23107811-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01579-
dc.contributor.localIdA01778-
dc.contributor.localIdA02889-
dc.contributor.localIdA04268-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA02824-
dc.relation.journalcodeJ00241-
dc.identifier.eissn1478-6362-
dc.identifier.pmid23107811-
dc.subject.keywordRheumatoid Arthritis-
dc.subject.keywordRheumatoid Arthritis Patient-
dc.subject.keywordChronic Liver Disease-
dc.subject.keywordLiver Fibrosis-
dc.subject.keywordCumulative Dose-
dc.contributor.alternativeNamePark, Yong Beom-
dc.contributor.alternativeNamePark, Hee Jin-
dc.contributor.alternativeNameLee, Sang Won-
dc.contributor.alternativeNameLee, Soo Kon-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.affiliatedAuthorPark, Yong Beom-
dc.contributor.affiliatedAuthorPark, Hee Jin-
dc.contributor.affiliatedAuthorLee, Soo Kon-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorLee, Sang Won-
dc.citation.volume14-
dc.citation.number5-
dc.citation.startPage232-
dc.identifier.bibliographicCitationARTHRITIS RESEARCH & THERAPY, Vol.14(5) : 232, 2012-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.